Beauty Health (NASDAQ:SKIN) Stock Rating Reaffirmed by DA Davidson

DA Davidson reaffirmed their buy rating on shares of Beauty Health (NASDAQ:SKIN) in a research note issued to investors on Friday, Benzinga reports. DA Davidson currently has a $5.00 target price on the stock.

Separately, Canaccord Genuity Group lifted their target price on Beauty Health from $2.50 to $3.00 and gave the stock a hold rating in a report on Thursday, February 29th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $6.50.

Beauty Health Price Performance

Shares of NASDAQ:SKIN remained flat at $3.61 during trading on Friday. The company had a trading volume of 2,732,594 shares, compared to its average volume of 2,970,931. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.27 and a current ratio of 6.07. Beauty Health has a 12-month low of $1.35 and a 12-month high of $13.90. The firm has a 50-day moving average of $3.08 and a 200-day moving average of $3.83. The firm has a market capitalization of $473.87 million, a P/E ratio of -4.69 and a beta of 0.94.

Beauty Health (NASDAQ:SKIN) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $96.80 million during the quarter, compared to analysts’ expectations of $87.22 million. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS. On average, sell-side analysts anticipate that Beauty Health will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Beauty Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Sierra Summit Advisors LLC bought a new position in shares of Beauty Health during the 4th quarter worth $856,000. Price T Rowe Associates Inc. MD grew its position in shares of Beauty Health by 38.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,347 shares of the company’s stock worth $216,000 after buying an additional 19,150 shares in the last quarter. Barclays PLC grew its position in shares of Beauty Health by 48.0% during the 4th quarter. Barclays PLC now owns 139,507 shares of the company’s stock worth $433,000 after buying an additional 45,220 shares in the last quarter. Numerai GP LLC bought a new position in shares of Beauty Health during the 4th quarter worth $567,000. Finally, Occudo Quantitative Strategies LP bought a new position in shares of Beauty Health during the 4th quarter worth $217,000.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health.